MAZE

31.3703.27%
DK

Daniel K. Spiegelman

Independent Non-Employee Director

Mr. Daniel K. Spiegelman, also known as Dan, M.B.A. is Independent Director of Bluejay Therapeutics, Inc. from November 2024. He is Independent Non-Employee Director of Maze Therapeutics, Inc. He is Independent Director of vTv Therapeutics Inc. from June 11, 2024. He serves as Venture Partner at Samsara Biocapital, LLC. He serves as Member of Board advisor of LIPAC Oncology, LLC. He had been an Independent Director of Kyverna Therapeutics, Inc. since April 2021 until February 24, 2026 and at Jiya Acquisition Corp since November 18, 2020. He had been Independent Director of Myriad Genetics, Inc. since May 27, 2020. He had been an Independent Non-Executive Director of Opthea Limited since September 10, 2020 until April 04, 2024. He has been a Director of Tizona Therapeutics, Inc. since May 2019. He was Director at Maze Therapeutics, Inc. since October 2020. He has served as the interim Chief Executive Officer of Recardia Therapeutics, Inc. since July 2020. He has been an Independent Director of Spruce Biosciences, Inc. since September 2020. He is the founder of Rapidscan Pharma Solutions, Inc. and served as its Director. From May 2009 to May 2012, he served as a consultant to provide strategic financial management support to a portfolio of public and private life science companies. He served as the Chief Financial Officer, Executive Vice President and Director at BioMarin Pharmaceutical Inc. since May 2012 until January 29, 2020. He served as the Chief Financial Officer of CV Therapeutics Inc. from January 1998 to May 2009 and served as its Senior Vice President since 1998 until May 2009. He was the Principal Accounting Officer of CV Therapeutics Inc. He joined CV Therapeutics in January 1998 and served as its Vice President from January 1998 to September 1999. He co-founded Rapidscan Pharma Solutions, Inc. in 2010 and serves as its Chief Executive Officer. He served as the Chief Financial Officer and Senior Vice President of Gilead Palo Alto, Inc. since September 1999 and served as its Principal Accounting Officer. He worked at Genentech, Inc. from July 1991 to January 1998 and served as its Treasurer from 1996 to 1998, Assistant Treasurer from 1992 to 1996 and Treasury Manager from 1991 to 1992. He was the Chairman of the Board and Director of Vifor Pharma, Inc. (formerly, Relypsa, Inc.) since June 19, 2014 until September 2016. He served as an Independent Director at Cascadian Therapeutics, Inc. from October 2008 to March 9, 2018 and Xcyte Therapies Inc. from September 8, 2004 to 2006. He serves as a Director of Rapidscan Pharma Solutions, Inc. He served as a Director at Anthera Pharmaceuticals, Inc. from February 2010 to June 23, 2014; Affymax, Inc. since October 6, 2006 until June 2013 and Omeros Corporation from December 2009 to June 21, 2012. He served as a Director at Cyclacel Pharmaceuticals Inc. from September 2004 to June 2012. Mr. Spiegelman has also served on the board of directors of Tiizona Therapeutics, Inc., a privately held biotechnology company since May 2019. He served as a Director of Jennerex Biotherapeutics Inc. He holds a Bachelor of Arts degree in Economics from the Stanford University and an MBA from Stanford Graduate School of Business.

Positions